Gentle Laser Treatment for Glaucoma.

SLT uses short pulses of low-energy laser light to selectively target pigmented cells in the trabecular meshwork — the eye’s natural drainage system. This stimulates a biological healing response that improves fluid outflow from the eye, resulting in lower intraocular pressure without causing thermal damage to surrounding tissue.

SLT (Selective Laser Trabeculoplasty) uses low-energy laser pulses that selectively target pigmented cells without causing thermal damage to surrounding tissue. ALT (Argon Laser Trabeculoplasty) uses higher energy and causes permanent scarring of the drainage tissue. Because SLT is non-destructive, it can be safely repeated, while ALT generally cannot.

Yes. The landmark LiGHT trial demonstrated that SLT is safe and effective as a first-line treatment for newly diagnosed open-angle glaucoma, even before starting eye drops. Many glaucoma specialists now offer SLT as an initial treatment option rather than beginning with daily medications, particularly for patients who want to avoid the burden of long-term drop compliance.

Clinical studies have shown that SLT typically lowers intraocular pressure by 20 to 30 percent, which is comparable to many prescription glaucoma eye drops. The exact reduction varies from patient to patient depending on baseline pressure, the type of glaucoma, and individual response to the laser.

SLT is virtually painless. Before the procedure begins, numbing eye drops are applied to ensure your complete comfort. Most patients feel nothing at all during the treatment. Some may notice a mild sensation of warmth or see a brief flash of light with each laser pulse, but there is no stinging, burning, or sharp discomfort. No needles or incisions are involved, and no sedation is necessary.

The SLT laser procedure itself takes approximately 5 to 10 minutes per eye. Including preparation, the application of numbing drops, and a brief post-treatment pressure check, your entire appointment will last about 60 to 90 minutes. You are free to drive yourself home and resume normal activities immediately afterward.

Most patients can drive themselves home after SLT. Your vision may be slightly blurry for a few hours due to the numbing drops and the contact lens used during the procedure, but this resolves quickly. If you prefer, you may arrange for someone to drive you as a precaution.

After SLT, your eye may be slightly red or feel mildly irritated for a few hours. Your vision may be temporarily blurry. A mild anti-inflammatory drop is typically prescribed for a few days. There is no recovery downtime — you can return to work and normal activities the same day. Your physicians will schedule a follow-up visit to check your pressure response.

For many patients, SLT can significantly reduce or even eliminate the need for daily glaucoma eye drops. Clinical studies, including the landmark LiGHT trial, have shown that SLT provides pressure reduction comparable to topical medications. Whether you can discontinue your drops depends on your individual response, your target eye pressure, and the severity of your glaucoma. Your physicians will carefully monitor your pressure after the procedure and advise you on whether your medications can be adjusted.

SLT results typically last between 1 and 5 years, with most patients experiencing effective pressure reduction for 2 to 3 years. The duration varies based on individual factors such as your type of glaucoma, baseline eye pressure, and overall eye health. One of the key advantages of SLT over older laser treatments is that it can be safely repeated if the pressure-lowering effect diminishes over time.

Yes. One of the key advantages of SLT over older laser treatments like ALT is that it does not cause permanent structural changes to the drainage tissue. This means the procedure can be safely repeated if the pressure-lowering effect fades over time, providing a renewable, sustainable long-term treatment strategy for your glaucoma.

Yes. SLT can be used alongside existing glaucoma eye drops to achieve additional pressure reduction when drops alone are not sufficient. It can also be performed in conjunction with MIGS procedures or cataract surgery when appropriate, allowing multiple conditions to be addressed efficiently in fewer visits.

SLT is most effective for open-angle glaucoma and ocular hypertension. It may not be appropriate for patients with angle-closure glaucoma, significant inflammation inside the eye, or certain types of secondary glaucoma. Your physicians will perform a thorough evaluation including gonioscopy to determine if SLT is right for your specific condition.

Yes. SLT is an FDA-approved, medically necessary procedure for glaucoma management and is covered by Medicare and most private insurance plans. It is not considered elective or cosmetic. Our team will verify your coverage and explain any out-of-pocket costs before your procedure.

SLT has an excellent safety profile. Serious complications are exceptionally rare. Some patients may experience a temporary increase in eye pressure, mild inflammation, or slight eye redness in the hours or days following the procedure. These effects are typically short-lived and resolve on their own or with a brief course of anti-inflammatory drops. The overall complication rate is very low compared to surgical alternatives.